| Literature DB >> 33940982 |
Carly E A Barbon1,2, Douglas B Chepeha3, Andrew J Hope4, Melanie Peladeau-Pigeon2, Ashley A Waito1,2, Catriona M Steele1,2.
Abstract
The current standard for the treatment of oropharynx cancers is radiation therapy. However, patients are frequently left with dysphagia characterized by penetration-aspiration (impaired safety) and residue (impaired efficiency). Although thickened liquids are commonly used to manage dysphagia, we lack evidence to guide the modification of liquids for clinical benefit in the head and neck cancer population. The objective of this study was to assess the impact of slightly and mildly thick liquids on penetration-aspiration and residue in 12 patients with oropharyngeal cancer who displayed penetration-aspiration on thin liquid within 3 to 6 months after completion of radiotherapy. Significantly fewer instances of penetration-aspiration were seen with slightly and mildly thick liquids as compared with thin (P < .05). No differences were found across stimuli in the frequency of residue. Patients with oropharyngeal cancers who present with post-radiation therapy dysphagia involving penetration-aspiration on thin liquids may benefit from slightly and mildly thick liquids without risk of worse residue.Entities:
Keywords: dysphagia; head and neck cancer; texture modification
Mesh:
Year: 2021 PMID: 33940982 PMCID: PMC8892064 DOI: 10.1177/01945998211010435
Source DB: PubMed Journal: Otolaryngol Head Neck Surg ISSN: 0194-5998 Impact factor: 3.497
Study Participant Demographics.
| Age, y | Site | Stage | Dose, cGy | Chemotherapy | HPV status | Days between RT and VFSS |
|---|---|---|---|---|---|---|
| 78 | Base of tongue | T2, N2b | 5200 | NA | + | 105 |
| 67 | Base of tongue | T3, N2b | 7000 | Cisplatin | − | 111 |
| 66 | Base of tongue | T2, N2b | 7000 | Cisplatin | + | 113 |
| 61 | Base of tongue | T3, N2b | 7000 | Cisplatin
| + | 113 |
| 58 | Oropharynx | T0, N2b | 7000 | Cisplatin
| + | 151 |
| 49 | Soft palate | T3, N2b | 7000 | Cisplatin | − | 140 |
| 77 | Soft palate | T1, N0 | 6000 | NA | − | 134 |
| 61 | Right tonsil | T2, N1 | 7000 | NA | + | 92 |
| 75 | Base of tongue | T1, N2b | 7000 | NA | + | 89 |
| 58 | Right tonsil/base of tongue | T2, N2c | 7000 | Cetuximab
| + | 111 |
| 60 | Left tonsil | T1, N2b | 7000 | Cisplatin (high dose) | + | 135 |
| 51 | Base of tongue | T3, N2b | 7000 | Cisplatin | + | 203 |
Abbreviations: HPV, human papillomavirus; NA, not applicable; RT, radiation therapy; VFSS, videofluoroscopic swallowing study.
All patients were male.
Full chemotherapy protocol not completed.
Figure 1.Pixel-based tracings of residue. (a) Pharyngeal residue. (b) Residue is traced and compared with an anatomic reference scalar (squared length of the C2-4 cervical spine), shown with white dashed lines.
Boluses Classified as Safe/Unsafe and Efficient/At Risk by Consistency.
| Penetration-Aspiration Scale | Residue | |||
|---|---|---|---|---|
| Stimulus | <3 (safe) | ≥3 (unsafe) | ≤1%(C2-4)
| >1%(C2-4)
|
| Thin | 60.70 | 39.30 | 53.80 | 46.20 |
| Slightly thick | 81.80 | 18.20 | 16.70 | 83.30 |
| Mildly thick | 81.80 | 18.20 | 16.70 | 83.30 |
| Total | 75.50 | 24.50 | 27.80 | 72.20 |
Values are presented as percentages.